This article refers to:
Article title: Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States
Authors: Roth JA, Sullivan SD, Lin VW, Bansala A, Purdum AG, Navale L, Cheng P, Ramsey SR
Journal: Journal of Medical Economics
Bibliometrics: Volume 21, Number 12, pages 1238–1245
DOI: https://doi.org/10.1080/13696998.2018.1529674
When this article was published online, there were errors in the article history dates.
These errors have now been corrected. The correct article history dates are:
Received 27 August 2018
Revised 18 September 2018
Accepted 25 August 2018